The Food and Drug Administration (FDA) issued draft guidance on recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of Human Immunodeficiency Virus (HIV) transmission by blood and blood products. The draft guidance is intended to provide blood establishments that collect blood or blood components, including Source Plasma, the following for individuals with increased risk of… (Slifer, January 27, 2023) #Food and Drug Administration, #Health Equity, #Prescription Drugs